MA32505B1 - 5-alcynyl-pyrimidines - Google Patents

5-alcynyl-pyrimidines

Info

Publication number
MA32505B1
MA32505B1 MA33560A MA33560A MA32505B1 MA 32505 B1 MA32505 B1 MA 32505B1 MA 33560 A MA33560 A MA 33560A MA 33560 A MA33560 A MA 33560A MA 32505 B1 MA32505 B1 MA 32505B1
Authority
MA
Morocco
Prior art keywords
pyrimidine
alkynyl
relates
compounds
drug
Prior art date
Application number
MA33560A
Other languages
Arabic (ar)
English (en)
Inventor
Tobias Wunberg
Ralph Brueckner
Dirk Kessler
Oliver Kraemer
Darryl Mcconnell
Siegfried Schneider
Der Veen Lars Van
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40202900&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA32505(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of MA32505B1 publication Critical patent/MA32505B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Laminated Bodies (AREA)
  • Application Of Or Painting With Fluid Materials (AREA)

Abstract

La présente invention porte sur des composés représentés par la formule générale (i) dans laquelle r1 à r4 sont tels que définis dans la revendication 1, qui sont appropriés pour le traitement de maladies caractérisées par une prolifération cellulaire excessive ou anormale. L'invention porte également sur l'utilisation de ces composés pour la préparation d'un médicament doté des propriétés mentionnées ci-dessus.
MA33560A 2008-07-29 2011-01-26 5-alcynyl-pyrimidines MA32505B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08161369 2008-07-29
PCT/EP2009/059763 WO2010012740A1 (fr) 2008-07-29 2009-07-28 5-alcynyl-pyrimidines

Publications (1)

Publication Number Publication Date
MA32505B1 true MA32505B1 (fr) 2011-07-03

Family

ID=40202900

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33560A MA32505B1 (fr) 2008-07-29 2011-01-26 5-alcynyl-pyrimidines

Country Status (25)

Country Link
US (1) US8916548B2 (fr)
EP (1) EP2323992B1 (fr)
JP (1) JP5599791B2 (fr)
KR (1) KR20110041536A (fr)
CN (1) CN102112450A (fr)
AR (1) AR072845A1 (fr)
AU (1) AU2009275957A1 (fr)
BR (1) BRPI0916679A2 (fr)
CA (1) CA2731909A1 (fr)
CL (1) CL2011000195A1 (fr)
CO (1) CO6341617A2 (fr)
DK (1) DK2323992T3 (fr)
EA (1) EA201100255A1 (fr)
EC (1) ECSP11010786A (fr)
ES (1) ES2597903T3 (fr)
HU (1) HUE029837T2 (fr)
IL (1) IL210343A0 (fr)
MA (1) MA32505B1 (fr)
MX (1) MX2011000729A (fr)
NZ (1) NZ590558A (fr)
PE (1) PE20110196A1 (fr)
PL (1) PL2323992T3 (fr)
TW (1) TW201010984A (fr)
UY (1) UY32009A (fr)
WO (1) WO2010012740A1 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010012740A1 (fr) 2008-07-29 2010-02-04 Boehringer Ingelheim International Gmbh 5-alcynyl-pyrimidines
AR072538A1 (es) 2008-07-29 2010-09-01 Boehringer Ingelheim Int Derivados de indolinonas, composiciones farmacéuticas y usos
AR076332A1 (es) * 2009-04-21 2011-06-01 Boehringer Ingelheim Int Derivados heterociclicos de 5-alquinil-piridinas, composiciones farmaceuticas que los comprenden y uso de los mismos para el tratamiento y/o prevencion del cancer, procesos inflamatorios, autoinmunes, y/o infecciones.
US8618111B2 (en) * 2010-01-26 2013-12-31 Boehringer Ingelheim International Gmbh 5-alkynyl-pyrimidines
US8633183B2 (en) * 2010-01-26 2014-01-21 Boehringer Ingelheim International Gmbh 5-alkynyl-pyrimidines
US8466162B2 (en) * 2011-01-26 2013-06-18 Boehringer Ingelheim International Gmbh 5-alkynyl-pyridines
TW201245176A (en) * 2011-01-26 2012-11-16 Boehringer Ingelheim Int New 5-alkynyl-pyridines
JP6016915B2 (ja) * 2011-07-28 2016-10-26 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ キナーゼ阻害剤として活性なアルキニル置換ピリミジニルピロール
UA110995C2 (uk) * 2011-10-07 2016-03-10 Ф. Хоффманн-Ля Рош Аг Етинільні похідні як модулятори метаботропного глутаматного рецептора
CA3161836A1 (fr) * 2013-12-11 2015-06-18 Celgene Quanticel Research, Inc. Inhibiteur de la demethylase-1 specifique de la lysine
KR102400920B1 (ko) * 2014-05-01 2022-05-20 셀젠 콴티셀 리서치, 인크. 리신 특이적 데메틸라제-1의 억제제
AU2015311805B2 (en) * 2014-09-05 2020-04-02 Celgene Quanticel Research, Inc. Inhibitors of lysine specific demethylase-1
CN104744376A (zh) * 2015-03-14 2015-07-01 长沙深橙生物科技有限公司 一种2-异丙基嘧啶衍生物的制备方法
CN104803921A (zh) * 2015-03-14 2015-07-29 长沙深橙生物科技有限公司 一种苯取代嘧啶衍生物的制备方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3832570A1 (de) * 1988-09-24 1990-03-29 Hoechst Ag 7-substituierte derivate der 3,5-dihydroxyhept-6-insaeure, verfahren zur ihrer herstellung, ihre verwendung als arzneimittel, sowie zwischenprodukte
EP0674627A1 (fr) 1992-12-18 1995-10-04 The Wellcome Foundation Limited Derives de pyrimidine, de pyridine, de pteridinone et d'indazole utilises comme inhibiteurs enzymatiques
US5622954A (en) 1994-05-11 1997-04-22 Fmc Corporation 5[W(substituted aryl)alkenylene and alkynylene]-2,4-diaminopyrimidines as pesticides
WO2001062233A2 (fr) * 2000-02-25 2001-08-30 F. Hoffmann La Roche Ag Modulateurs de recepteurs de l'adenosine
JP5154728B2 (ja) * 2000-07-24 2013-02-27 クレニツキー・ファーマシューティカルズ，インコーポレイテッド 神経栄養活性を有する置換５−アルキニルピリミジン
CA2528938A1 (fr) * 2003-06-13 2005-02-24 Zentaris Gmbh Composes presentant une activite inhibitrice de la phosphatidylinositol 3-kinase
ATE402705T1 (de) 2003-12-24 2008-08-15 Astrazeneca Ab Pyrimidine mit tie2 (tek) aktivität
WO2005113556A1 (fr) * 2004-05-13 2005-12-01 Icos Corporation Quinazolinones utilisees en tant qu'inhibiteurs de la phosphatidylinositol 3-kinase delta humaine
US7776869B2 (en) * 2004-10-18 2010-08-17 Amgen Inc. Heteroaryl-substituted alkyne compounds and method of use
US20080146599A1 (en) 2005-02-01 2008-06-19 Astrazeneca Ab Pyrimidine Compounds Having Tie-2 (Tek) Inhibitory Activity
EP1863805A1 (fr) 2005-02-01 2007-12-12 AstraZeneca AB Derives de pyrimidine presentant une activite inhibitrice de tie2 (tek)
US20070135437A1 (en) 2005-03-04 2007-06-14 Alsgen, Inc. Modulation of neurodegenerative diseases
WO2006106721A1 (fr) 2005-03-30 2006-10-12 Shionogi & Co., Ltd. Dérivé de pyrimidine ayant un effet d'inhibition de la tyrosine kinase
JP2008534565A (ja) 2005-03-31 2008-08-28 アストラゼネカ アクチボラグ Ｔｉｅ２阻害活性のあるアミノピリミジン誘導体
US7989622B2 (en) * 2005-10-07 2011-08-02 Exelixis, Inc. Phosphatidylinositol 3-kinase inhibitors and methods of their use
JO2660B1 (en) * 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
EP2057129A1 (fr) 2006-08-24 2009-05-13 AstraZeneca AB Dérivés de morpholino pyrimidine utiles dans le traitement de désordres prolifératifs
AU2007341228B2 (en) 2006-12-29 2013-04-18 Janssen Sciences Ireland Uc HIV inhibiting 5,6-substituted pyrimidines
EP2022785A1 (fr) 2007-06-20 2009-02-11 Bayer Schering Pharma Aktiengesellschaft Alkynylpyrimidines comme inhibiteurs de la kinase Tie2
WO2010012740A1 (fr) 2008-07-29 2010-02-04 Boehringer Ingelheim International Gmbh 5-alcynyl-pyrimidines
US8633183B2 (en) 2010-01-26 2014-01-21 Boehringer Ingelheim International Gmbh 5-alkynyl-pyrimidines

Also Published As

Publication number Publication date
WO2010012740A1 (fr) 2010-02-04
HUE029837T2 (en) 2017-04-28
CL2011000195A1 (es) 2011-07-08
MX2011000729A (es) 2011-03-15
KR20110041536A (ko) 2011-04-21
CN102112450A (zh) 2011-06-29
BRPI0916679A2 (pt) 2015-11-17
AR072845A1 (es) 2010-09-22
EP2323992A1 (fr) 2011-05-25
UY32009A (es) 2010-02-26
PL2323992T3 (pl) 2017-01-31
US8916548B2 (en) 2014-12-23
JP2011529468A (ja) 2011-12-08
PE20110196A1 (es) 2011-04-03
US20110281838A1 (en) 2011-11-17
EP2323992B1 (fr) 2016-07-20
DK2323992T3 (en) 2016-10-31
ES2597903T3 (es) 2017-01-24
TW201010984A (en) 2010-03-16
JP5599791B2 (ja) 2014-10-01
IL210343A0 (en) 2011-03-31
CA2731909A1 (fr) 2010-02-04
CO6341617A2 (es) 2011-11-21
ECSP11010786A (es) 2011-02-28
NZ590558A (en) 2012-12-21
EA201100255A1 (ru) 2011-08-30
AU2009275957A1 (en) 2010-02-04

Similar Documents

Publication Publication Date Title
MA32505B1 (fr) 5-alcynyl-pyrimidines
MA32811B1 (fr) Nouveaux composés
MA33939B1 (fr) 5-alcynyl-pyrimidines
MY153971A (en) Sulfonamides as trpm8 modulators
ECSP078060A (es) 2,4-diamino-pirimidinas como inhibidores de aurora
TN2011000279A1 (en) Novel pyrazole -4-n-alkoxycarboxamides as microbiocides
EA201190235A1 (ru) Замещенные 1-цианоэтилгетероциклилкарбоксамидные соединения 750
WO2010034838A3 (fr) Nouveaux composés chimiques
MA33937B1 (fr) Composes pyrazole comme antagonistes du recepteur crth2
EA201101330A1 (ru) Замещенные пиримидины, предназначенные для лечения рака
WO2009124962A3 (fr) Sulfonamides
GEP20135959B (en) Aryl piperazine and their usage as alpha2c antagonists
EA201100254A1 (ru) Новые соединения
TN2011000355A1 (en) Novel microbiocides
IN2012DN03846A (fr)
MX2010009837A (es) Tiazolil-dihidro-indazoles.
TN2011000531A1 (en) 5- alkynyl - pyridines
DE602006010738D1 (de) Pyrroloä2,3-cüpyridinderivate
DE602008002598D1 (en) Cyclohexylderivate
IN2012DN06600A (fr)
EA201101537A1 (ru) Тиатриазациклопентазулены в качестве ингибиторов pi3-киназ, предназначенные для лечения рака
ATE479691T1 (de) 4,5,6,7-tetrahydrothienoä2,3-cüpyridine als h3- modulatoren
MX2014004853A (es) 1-cicloalquil- o 1-heterociclil-hidroxiimino-3-fenil-propanos.
TN2011000049A1 (en) 5-alkynyl-pyrimidines
UA107920C2 (en) Substituted pyrimidine for the treatment of diseases such as cancer